ProPhase Labs Inc. (DE) (PRPH)
$0.02
$0.00
(-15.60%)
As on 28-Aug-2026 11:58EDT
Market cap
$0 Mln
Revenue (TTM)
$3 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-5.4 %
-
ROCE
-- %
-
Industry P/E
21.06
-
EV/EBITDA
7.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.1
-
Face value
--
-
Shares outstanding
14,016,204
10 Years Aggregate
CFO
$-11.99 Mln
EBITDA
$7.04 Mln
Net Profit
$28.31 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ProPhase Labs Inc. (DE) (PRPH)
| -95.3 | -65.7 | -80.6 | -99.4 | -92.6 | -79.2 | -49.4 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
ProPhase Labs Inc. (DE) (PRPH)
| -94.1 | -83.0 | -53.1 | 34.3 | -21.9 | 366.0 | -37.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ProPhase Labs Inc. (DE) (PRPH)
|
0.0 | 0.3 | 3.2 | -22.6 | -392.4 | -- | -- | 0.4 |
| 178.0 | 5,778.9 | 1,085.9 | 164.4 | 20.3 | 12.8 | 35.3 | 4.4 | |
| 43.5 | 2,779.1 | 3,084.1 | 166.3 | 8.7 | 10 | 16.4 | 1.6 | |
| 37.6 | 2,405.4 | 3,084.1 | 166.3 | 8.7 | 10 | 14.1 | 1.4 | |
| 63.7 | 10,705.4 | 6,555.5 | 597.9 | 14.7 | 11.8 | 18 | 2.0 | |
| 70.7 | 3,554.6 | 1,177.3 | 203.5 | 13.4 | 16.6 | 19.3 | 2.9 | |
| 31.6 | 7,679.0 | 18,436.0 | 545.6 | 5.2 | 14.7 | 13.6 | 2.0 | |
| 84.8 | 3,573.7 | 8,412.5 | 293.0 | 9.7 | 8.9 | 14.5 | 1.2 | |
| 3,919.5 | 4,080.2 | 10,272.0 | 634.0 | 4.2 | 11.8 | 6.5 | 0.8 | |
| 41.1 | 3,132.0 | 734.7 | 95.5 | 17.7 | 10.1 | 32.6 | 3.3 |
Shareholding Pattern
View DetailsAbout ProPhase Labs Inc. (DE) (PRPH)
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements... under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA). It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Uniondale, New York. Read more
-
Chairman & CEO
Mr. Ted William Karkus
-
Chairman & CEO
Mr. Ted William Karkus
-
Headquarters
Uniondale, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for ProPhase Labs Inc. (DE) (PRPH)
What is the current share price of ProPhase Labs Inc (DE) (PRPH) Today?
The share price of ProPhase Labs Inc (DE) (PRPH) is $0.02 (NASDAQ) as of 28-Aug-2026 11:58 EDT. ProPhase Labs Inc (DE) (PRPH) has given a return of -92.62% in the last 3 years.
What is the current PB & PE ratio of ProPhase Labs Inc (DE) (PRPH)?
Since, TTM earnings of ProPhase Labs Inc (DE) (PRPH) is negative, P/E ratio is not available.
The P/B ratio of ProPhase Labs Inc (DE) (PRPH) is 0.37 times as on 21-Aug-2026, a 78 discount to its peers’ median range of 1.71 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.27 |
1.14 |
2024 |
-0.42 |
3.08 |
2023 |
-0.49 |
0.17 |
2022 |
0.85 |
0.25 |
2021 |
1.76 |
0.19 |
What is the 52 Week High and Low of ProPhase Labs Inc (DE) (PRPH)?
The 52-week high and low of ProPhase Labs Inc (DE) (PRPH) are Rs 6.66 and Rs 0.00 as of 29-Aug-2026.
What is the market cap of ProPhase Labs Inc (DE) (PRPH)?
ProPhase Labs Inc (DE) (PRPH) has a market capitalisation of $ 0 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in ProPhase Labs Inc (DE) (PRPH)?
Before investing in ProPhase Labs Inc (DE) (PRPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.